Fortress Biotech
FBIO
53 hedge funds and large institutions have $15M invested in Fortress Biotech in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 11 closing their positions.
0% more funds holding
Funds holding: 53 → 53 (0)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
1.39% less ownership
Funds ownership: 18.65% → 17.27% (-1.4%)
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
41% less capital inflows, than outflows
Capital inflows: $2.52M | Capital outflows: $4.23M
49% less call options, than puts
Call options by funds: $585K | Put options by funds: $1.16M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSA Capital Partners
London,
United Kingdom
|
+$741K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$613K |
| 3 |
XTX Topco
George Town,
Cayman Islands
|
+$209K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$198K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$137K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Summit Financial
Parsippany,
New Jersey
|
-$1.42M |
| 2 |
Sculptor Capital
New York
|
-$533K |
| 3 |
Corient Private Wealth
Miami,
Florida
|
-$278K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$216K |
| 5 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
-$215K |
FBIO Hedge Fund Activity: Q1 2026 in Review
53 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q1 2026, worth a combined $15M — down 30% from $21.2M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of FBIO and 10 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 11 added.
The largest buyer was GSA Capital Partners, adding an estimated $741K. The largest seller was Summit Financial, cutting an estimated $1.42M.
- 53 institutional investors held Fortress Biotech (FBIO) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $15M of Fortress Biotech stock for Q1 2026, down 30% quarter-over-quarter.
- 10 funds opened new Fortress Biotech positions in Q1 2026 and 11 closed out, a net change of -1 holder.
- The largest Fortress Biotech buyer in Q1 2026 was GSA Capital Partners, an estimated $741K added.
- The largest Fortress Biotech seller in Q1 2026 was Summit Financial, an estimated $1.42M sold.
Based on aggregated 13F filings for Q1 2026.